Alopecia Areata
Pipeline by Development Stage
Drug Modality Breakdown
On Market (2)
Approved therapies currently available
Competitive Landscape
10 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 16 trials with date data
Clinical Trials (16)
Total enrollment: 55,371 patients across 16 trials
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Regeneron AA Multicenter (Dupilumab)
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
A Study of Secukinumab for the Treatment of Alopecia Areata
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Litfulo Capsules Special Investigation
Quantification of the Socio-economic Multifacet Burden of Alopecia Areata and Identification of the Associated Factors
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata